Chapter 4 A dysfunctional T cell gene signature for predicting non-response to PD‑1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics Karlijn Hummelink1,2, Renaud Tissier3, Linda J.W. Bosch1, Oscar Krijgsman4, Michel M. van den Heuvel2,5, Willemijn S.M.E. Theelen2, Diane Damotte6,7,8, François Goldwasser7,8, Karen Leroy6,7,8,9, Egbert F. Smit2,10, Gerrit A. Meijer1,#, Daniela S. Thommen4,#, and Kim Monkhorst1,# #Shared last authorship. 1Department of Pathology, Division of Diagnostic Oncology, 2Department of Thoracic Oncology, Division of Medical Oncology, 3Biostatistics Unit, 4Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, The Netherlands, 5Present address: Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands, 6Team Cancer, Immune Control and Escape, Cordeliers Research Center, UMRS 1138, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France, 7University Paris Cité, Paris, France, 8CERTIM, Medical Oncology, Hôpital Cochin, APHP, Paris, France, 9Department of Biochemistry, Hôpital Cochin, Européen Georges Pompidou, APHP Centre, 75015, Paris, France, 10Present address: Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands. Clinical Cancer Research, 2024
RkJQdWJsaXNoZXIy MTk4NDMw